Despite recent failures, a flurry of activity in biotech and pharma is raising hopes that an effective drug for this fatal lung disease is on the way. Ken Garber investigates.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The multifaceted roles of FOXM1 in pulmonary disease
Cell Communication and Signaling Open Access 16 April 2019
-
IL-32γ attenuates airway fibrosis by modulating the integrin-FAK signaling pathway in fibroblasts
Respiratory Research Open Access 26 September 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Katie Vicari
References
Noble, P.W. et al. Lancet 377, 1760–1769 (2011).
Raghu, G. et al. Am. J. Respir. Crit. Care Med. 183, 788–824 (2011).
Barry-Hamilton, V. et al. Nat. Med. 16, 1009–1017 (2010).
Tager, A.M. et al. Nat. Med. 14, 45–54 (2008).
Richeldi, L. et al. N. Engl. J. Med. 365, 1079–1087 (2011).
Maher, T.M. Eur. Respir. Rev. 22, 148–152 (2013).
Idiopathic Pulmonary Fibrosis Clinical Research Network. N. Engl. J. Med. 366, 1968–1977 (2012).
Van Den Blink, B. et al. American Thoracic Society meeting abstract A5707 (2013).
Rights and permissions
About this article
Cite this article
At the frontiers of lung fibrosis therapy. Nat Biotechnol 31, 781–783 (2013). https://doi.org/10.1038/nbt.2687
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2687
This article is cited by
-
The multifaceted roles of FOXM1 in pulmonary disease
Cell Communication and Signaling (2019)
-
IL-32γ attenuates airway fibrosis by modulating the integrin-FAK signaling pathway in fibroblasts
Respiratory Research (2018)
-
Landmark approvals in idiopathic pulmonary fibrosis
Nature Biotechnology (2014)
